Loading…
Decision Guide
Reimbursement below acquisition is now a documented, sector-wide problem — 97% of practices in one specialty-society survey had experienced it. But “drop the drug” is the sixth-best response, not the first. Here are the six levers, in the order they cost you least.
Same-molecule products carry separate codes and separate payment limits that can differ by 2× or more inside one family. A line that's underwater on one product may be positive one row away — subject to payer coverage, interchangeability rules, and your P&T process. This is the cheapest fix on the list, and it's the one the payment-limit data can show you directly.
The same market forces dragging the payment limit down are dragging street acquisition down — your invoice just hasn't caught up. The quarterly file is public evidence: when the limit on a product falls 20% and your acquisition hasn't moved, that delta is your renegotiation opener. Distributors reprice fastest for practices that ask with the number in hand.
A drug can look underwater when the real problem is operational: discarded units billed without the JW modifier (unreimbursed waste), coinsurance that never gets collected (20% of the allowable — bigger than the entire add-on), and preventable denials. At thin margins, full coinsurance collection is frequently the difference between a negative line and a positive one.
"Underwater" at the Medicare limit doesn't mean underwater across your book. Commercial contracts typically pay a different — often higher — multiple of ASP, so the same vial can lose money on Medicare and earn on commercial. Before dropping a drug, separate the math by payer: the decision is per book, not per molecule.
Most commercial medical-benefit contracts price drugs as ASP plus a percentage. When ASP collapses, the contract's percentage stops covering acquisition — which is a renegotiation argument, not just a complaint. Practices that bring the published trend line to the payer conversation are negotiating from documentation, not anecdote.
Dropping a drug shifts patients to higher-cost sites of care and is exactly the outcome the specialty societies are warning regulators about — an ACR-led coalition of 40+ organizations has asked CMS to address underwater reimbursement directly. If you get here, document the math: the same numbers justify the decision internally and feed the advocacy case.
Only if street prices have stopped falling. The limit is set from sales data two quarters old, so in a steadily declining market the limit is always above where prices are heading but below what you paid two quarters ago — the lag stays against you until the price curve flattens. Check the product's trend page: a decelerating decline is the early signal.
Advocacy is active — specialty societies have proposed ASP floors and lag fixes, and the issue is on CMS's radar — but as of mid-2026 no enacted change protects a practice from underwater reimbursement. Plan with the rules as they are.
Yes — any drug whose price is falling faster than the two-quarter lag can go underwater (generic injectables are the other classic case). Biosimilar families just concentrate the dynamic, because competitive entry triggers the steepest declines and the same-family escape hatch only exists there.
Why limits fall in the first place: ASP+6 after sequestration, explained. Per-drug history: the trend pages.
Drug economics as of Q3 2026 (Medicare ASP basis)
The practice X-Ray answers it from your own 835s: every drug, every payer, the actual realized rates — and which of the six levers is worth the most for your book.